

**REMARKS**

The foregoing amendments are presented to place the application in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825.

Enclosed herewith is a substitute Sequence Listing in both paper and computer readable form as required by 37 C.F.R. § 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.


The substitute Sequence Listing corrects the errors noted in the Notice to Comply. A copy of the Notice is attached herewith as required. The substitute Sequence Listing has been run through the PTO Checker software (version 4.4.0) and no errors were found.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825.

Favorable action on the merits is respectfully requested.

Respectfully submitted,

Toshikazu NAKAMURA et al.

By: 

Jay F. Williams

Registration No. 48,036

Attorney for Applicants

JFW/akl  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
November 30, 2006

Attorney Docket No. 2006\_0825A  
Serial No. 10/582,973  
November 30, 2006

**ATTACHMENTS**

1. Substitute Sequence Listing (paper copy & CRF);
2. Copy of Notification to Comply with Requirements for Patent Applications  
Containing Nucleotide and/or Amino Acid Sequence Disclosures dated November  
9, 2006.